Skip to main content

Advertisement

SpringerLink
Log in

Clinical characteristics of influenza virus infection in juvenile idiopathic arthritis patients treated with tocilizumab

  • Original Article
  • Published:
Modern Rheumatology

Abstract

Background

Inhibition of interleukin-6 (IL-6) signaling by tocilizumab is highly effective for treatment of refractory juvenile idiopathic arthritis (JIA). It appears that IL-6 plays an important role in the immune response to the influenza virus, but it is not clear whether treatment with tocilizumab affects the severity of influenza.

Methods

We retrospectively collected clinical and laboratory data from JIA patients (n = 33) treated with tocilizumab. Ten patients who developed influenza (tocilizumab group; 10.1 %, 10/99 patient-years) were analyzed. Eleven JIA patients who experienced influenza during conventional treatments, without tocilizumab (control group), were compared with the tocilizumab group.

Results

Of the 10 patients in the tocilizumab group, 6 patients did not have high fever (>38 °C), and the other 4 febrile patients recovered from fever in 1 day. White blood cell counts and lymphocyte counts were significantly lower at the acute phase of infection compared with data from before influenza infection. The degree of fever and level of C-reactive protein in the tocilizumab group were significantly reduced compared with the control group.

Conclusions

IL-6 inhibition by tocilizumab reduced inflammation associated with infection and resulted in mild symptoms during influenza. Leukopenia might be a useful indicator of viral infection, including influenza, during tocilizumab treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–78.

    Article  PubMed  CAS  Google Scholar 

  2. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998–1006.

    Article  PubMed  CAS  Google Scholar 

  3. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Investig. 2011;121(9):3375–83.

    Article  PubMed  CAS  Google Scholar 

  4. Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology. 2011;50(3):552–62.

    Article  PubMed  CAS  Google Scholar 

  5. Nicholson KG. Clinical features of influenza. Semin Respir Infect. 1992;7(1):26–37.

    PubMed  CAS  Google Scholar 

  6. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9(8):493–504.

    Article  PubMed  Google Scholar 

  7. Fujiwara H, Nishimoto N, Hamano Y, Asanuma N, Miki S, Kasayama S, et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol Jpn Rheum Assoc. 2009;19(1):64–8.

    Article  Google Scholar 

  8. Dienz O, Rud JG, Eaton SM, Lanthier PA, Burg E, Drew A, et al. Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. Mucosal Immunol. 2012;5(3):258–66.

    Article  PubMed  CAS  Google Scholar 

  9. Longhi MP, Wright K, Lauder SN, Nowell MA, Jones GW, Godkin AJ, et al. Interleukin-6 is crucial for recall of influenza-specific memory CD4 T cells. PLoS Pathog. 2008;4(2):e1000006.

    Article  PubMed  Google Scholar 

  10. Dienz O, Eaton SM, Bond JP, Neveu W, Moquin D, Noubade R, et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med. 2009;206(1):69–78.

    Article  PubMed  CAS  Google Scholar 

  11. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Investig. 1998;101(3):643–9.

    Article  PubMed  CAS  Google Scholar 

  12. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009;460(7258):1021–5.

    PubMed  CAS  Google Scholar 

  13. Le Goffic R, Balloy V, Lagranderie M, Alexopoulou L, Escriou N, Flavell R, et al. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog. 2006;2(6):e53.

    Article  PubMed  Google Scholar 

  14. Silvennoinen H, Peltola V, Lehtinen P, Vainionpaa R, Heikkinen T. Clinical presentation of influenza in unselected children treated as outpatients. Pediatr Infect Dis J. 2009;28(5):372–5.

    Article  PubMed  Google Scholar 

  15. Shinoki T, Hara R, Kaneko U, Miyamae T, Imagawa T, Mori M, et al. Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab. Mod Rheumatol. 2012; [Epub ahead of print].

  16. Chiappini E, Galli L, Azzi A, Resti M, Bonsignori F, de Martino M. Lymphocytopenia as a marker for pandemic influenza A/H1N1 2009 virus infection in children. J Med Virol. 2011;83(1):1–4.

    Article  PubMed  Google Scholar 

  17. Nakamura I, Omata Y, Naito M, Ito K. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis. J Rheumatol. 2009;36(2):459–60.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan

    Jun-ichi Kawada & Yoshinori Ito

  2. Department of Infection and Immunology, Aichi Children’s Health and Medical Center, 1-2 Osakada, Morioka-cho, Obu, Aichi, 474-8710, Japan

    Jun-ichi Kawada, Yoshiro Kitagawa & Naomi Iwata

Authors
  1. Jun-ichi Kawada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshiro Kitagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naomi Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshinori Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun-ichi Kawada.

About this article

Cite this article

Kawada, Ji., Kitagawa, Y., Iwata, N. et al. Clinical characteristics of influenza virus infection in juvenile idiopathic arthritis patients treated with tocilizumab. Mod Rheumatol 23, 972–976 (2013). https://doi.org/10.1007/s10165-012-0780-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-012-0780-0

Keywords

Search

Navigation